NRX-101 Development Expanded to Include TMS for Depression
January 15, 2026
Treatment resistance is common in major depressive disorder, and tr...
Read More
Heart Rate, Cholesterol, and Weight Shifts Vary Widely Across Antidepressant Classes
December 18, 2025
Antidepressants remain among the most prescribed psychotropics worl...
Read More
FDA Approves Lumateperone as Adjunctive Treatment for Major Depressive Disorder
November 6, 2025
The FDA has approved lumateperone as an adjunctive therapy with an...
Read More
Lurasidone Efficacious for Depression Across Psychiatric Diagnoses
October 10, 2025
Depressive symptoms are a key driver of morbidity across multiple p...
Read More
Antidepressant Discontinuation Symptoms
July 28, 2025
Understanding the true incidence and severity of antidepressant dis...
Read More
Esketamine Monotherapy in Adults With Treatment-Resistant Depression
July 24, 2025
A new phase 4 randomized controlled trial evaluated the efficacy of...
Read More
Lithium Versus Quetiapine Augmentation For Treatment-Resistant Depression
July 8, 2025
A major randomized controlled trial compared the long-term clinical...
Read More
Esketamine Combinations in TRD: SNRI vs SSRI Outcomes
June 20, 2025
In a large real-world comparative effectiveness study involving ove...
Read More
Psilocybin and Escitalopram Show Distinct Brain Effects in Depression Treatment
June 11, 2025
A new randomized controlled trial directly compared the brain effec...
Read More
Trial Results of Solriamfetol in MDD With/Without Excessive Daytime Sleepiness
May 18, 2025
A new phase 3 proof-of-concept trial offers early evidence that sol...
Read More
Accelerated Theta-Burst Stimulation for Treatment-Resistant Depression
April 14, 2025
A recent study provides compelling evidence supporting the use of a...
Read More
New Research Links Depression to Increased Risk of Multiple Chronic Diseases
March 27, 2025
Mood disorders are increasingly viewed as whole-body conditions aff...
Read More